Sugemalimab Monotherapy for Patients With Relapsed or Refractory Extranodal Natural Killer/T-Cell Lymphoma (GEMSTONE-201): Results From a Single-Arm, Multicenter, Phase II Study

Relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) is a rare and aggressive type of non-Hodgkin lymphoma with limited treatment options. This phase II study evaluated the efficacy and safety of sugemalimab, an anti–PD-L1 monoclonal antibody, in R/R ENKTL. METHODS: Eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Huiqiang, Tao, Rong, Hao, Siguo, Yang, Yu, Cen, Hong, Zhou, Hui, Guo, Ye, Zou, Liqun, Cao, Junning, Huang, Yunhong, Jin, Jie, Zhang, Liling, Yang, Haiyan, Xing, Xiaojing, Zhang, Huilai, Liu, Yanyan, Ding, Kaiyang, Qi, Qinzhou, Zhu, Xiaoli, Zhu, Dan, Wang, Siyuan, Fang, Teng, Dai, Hangjun, Shi, Qingmei, Yang, Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414714/
https://www.ncbi.nlm.nih.gov/pubmed/36996373
http://dx.doi.org/10.1200/JCO.22.02367

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414714/
https://www.ncbi.nlm.nih.gov/pubmed/36996373
http://dx.doi.org/10.1200/JCO.22.02367

Ejemplares similares